Daniel E. Geffken
2021 - Sevion Therapeutics
In 2021, Daniel E. Geffken earned a total compensation of $130.8K as Interim Chief Financial Officer at Sevion Therapeutics.
Compensation breakdown
| Other | $130,750 |
|---|---|
| Total | $130,750 |
Geffken received $130.8K in other compensation, accounting for 100% of the total pay in 2021.
Rankings
In 2021, Daniel E. Geffken's compensation ranked 12,182nd out of 12,406 executives tracked by ExecPay. In other words, Geffken earned more than 1.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 12,182 out of 12,406 | 2nd |
Division Manufacturing | 5,392 out of 5,494 | 2nd |
Major group Chemicals And Allied Products | 2,337 out of 2,369 | 1st |
Industry group Drugs | 2,062 out of 2,090 | 1st |
Industry Biological Products, Except Diagnostic Substances | 446 out of 452 | 1st |
Source: SEC filing on April 28, 2023.
Geffken's colleagues
We found two more compensation records of executives who worked with Daniel E. Geffken at Sevion Therapeutics in 2021.